Printer Friendly

City of Hope obtains United States patent.

City of Hope (Duarte, CA) has patented genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc:.zeta. receptor where Fv designates the V.sub.H and V.sub.L chains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge-C.sub.H2-C.sub.H3 region of a human IgG.sub.1, and .zeta. represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed. (US 7,354,762)
COPYRIGHT 2008 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Mar 1, 2008
Previous Article:National Institute of Agrobiological Sciences obtains United States patent.
Next Article:Mitsukan obtains United States patent.

Related Articles
Mediscience Japanese patent issued covering technique to distinguish normal and benign tissue from cancerous tissue
Boston Scientific describes damage award as excessive.
Boston Scientific announces court decision on stent technology.
MorphoSys widens scope of United States patent for HuCAL technology.
Federal Court of Appeals to decide on claims for United States in fraud case against Hoffmann-La Roche.
Patent covers prehistoric and aged DNA technology - could solve ancient puzzles, criminal cold cases.
The "Hatch" factor: is intellectual property reform on the horizon?

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters